Breadcrumb Home Resources and Information Physicians and Scientists Resource Hub Efficacy, Safety and Predictive Biomarker of Third-generation Tyrosine Kinase Inhibitors With Azacitidine In Myeloid Blast Phase of Chronic Myeloid Leukemia Efficacy, safety and predictive biomarker of third-generation tyrosine kinase inhibitors with azacitidine in myeloid blast phase of chronic myeloid leukemia Cancer , Nov 2025 Bao M et al. Cancer, November 2025 – open access publication Share Tweet Share Share